Most of Elevance's $2 guidance raise sits outside the base for next year's target

Elevance Health raised its guidance for this year's adjusted earnings per share to at least $29, $2 more than it guided in July. The figure the company will build next year on moved much less. Its earnings baseline, the number from which it measures a target of at least 12% growth in adjusted EPS next year, rose by $0.75 to at least $26.75.

Most of the gap comes from the insurer's investment portfolio. Adjusted EPS of $6.99 in the September 2026 quarter included a net non-operating benefit of $1.85 a share, which the chief financial officer attributed mainly to valuation adjustments within investment income, partly offset by state tax items. The chief financial officer, Mark Kaye, credited about half a dollar a share to better operations. By the company's own definition the baseline leaves out non-recurring investment income and other non-operating items, and also the targeted one-time investments it has been funding. The baseline therefore took in the operating beat and a better outlook for individual ACA plans, while the investment gain lifted only the headline guidance.

Something similar happened earlier in the year: the company reported nonrecurring investment income in the first quarter and a net benefit from items below the operating line in the second. Valuation gains are real money in the period they are booked, and the nonrecurring label is the company's. But it does not count them toward what it expects to earn again.

Take the investment line away and the quarter's operations were flat. Adjusted operating gain across the reportable segments was slightly below its level a year earlier. Spending absorbed whatever the business saved on medical costs: the adjusted operating expense ratio, running costs as a share of operating revenue, rose to 11.3% from 10.4%. Kaye linked it to the same programme: "This quarter, we again made targeted onetime investments in member experience, medical cost management and Carelon's value-based solutions." Adjusted EPS still rose from a year earlier, carried by higher net investment income and a smaller diluted share count after buybacks.

Inside that flat total the businesses moved apart. Health Benefits, the plans that carry Medicaid, Medicare and employer members, earned less in reported operating gain than a year earlier, while the CarelonRx pharmacy business and Carelon Services made up most of the difference. The company put the segment's decline down to its targeted investments, partly offset by a better benefit expense ratio.

The baseline also looks modest set against last year. Taking out the favourable nonrecurring items the company identified in its full-year results leaves underlying adjusted EPS of $26.54 for last year, calculated from its reported figures, so the new baseline sits only $0.21 higher. Growth of at least 12% from the baseline implies at least $29.96 a share next year, again calculated from the company's target, a little above the guidance for this year that includes the investment gains.

Getting there depends on things the company has described but not sized for next year. It still describes this year as the low point for Medicaid margins, expects improvement next year and now sees this year's Medicaid margin slightly ahead of the outlook it gave in July. It expects at least 1.2 million individual ACA members at year-end, more than it guided in July. And the roughly $0.80 a share of one-time investments, funded from the second quarter's below-the-line gain, must not recur; in July the company said that spending belonged to this year only and was not part of 2027. Kaye also flagged a nonrecurring discrete tax item in the fourth quarter, which partly offsets this year's raise.